Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 129

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 129
---
 will have, a direct or indirect material interest. CERo Relationships and Related Party Transactions Collaboration and Option Agreement On March 3, 2020, Legacy CERo entered into a collaboration and option agreement (“Collaboration Agreement”) with a collaborative partner that was an investor of Legacy CERo, pursuant to which each party was granted a royalty -free, nonexclusive, worldwide license to share the other party’s technologies to create bi -functionalT -cells. Legacy CERo was responsible for all employee and other internal costs incurred in the performance of all of Legacy CERo’s R&D activities, with approved cost overruns funded by the collaborative partner. At the end of the research project, the collaborative partner would be granted the option to enter into an exclusive license for the further development of the combined drug. Under the Collaboration Agreement, the collaborative partner paid us $0 for the year ended December 31, 2023. The Collaboration Agreement terminated on March 3, 2023. PIPE Financings In February 2024, we issued and sold an aggregate of 10,039shares of Series A Preferred Stock, 6,127 Series A Warrants and 2,500 Preferred Warrants, at a price of $1,000 per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $8.0 million, plus additional cash proceeds of up to $2.0 million if the Preferred Warrants are exercised. The following table summarizes the shares of our Series A Preferred Stock issued to our related parties:

| Purchasers(1)                          |     | Shares of 
  Series A 
 Preferred 
     Stock |     | Total    
 Purchase 
 Price    |           |
|:---------------------------------------|:----|----------:|:----|:---------|----------:|
| Daniel Corey(2)                        |     |       150 |     | $        |   150,000 |
| Atwood-Edminster Trust dtd 4-2-2000(3) |     |     1,002 |     | $        | 1,002,000 |
| Chris Ehrlich(4)                       |     |       275 |     | $        |   275,000 |
| Phoenix Biotech Sponsor, LLC(5)        |     |     1,380 |     | $        | 1,380,000 |

____________ (1)Additional details regarding these stockholders and their equity holdings are included in this proxy statement under